Aug 2026· Cell Reports Medicine· pp.
102992
· 0 citations· 129 references
Medicine
TL;DR
This review traces key field milestones and analyzes prospects and hurdles for next-generation iPSC therapies as autologous and allogeneic iPSC therapies complement each other for distinct clinical demands.
Abstract
Induced pluripotent stem cell (iPSC)-based treatments have revolutionized regenerative medicine, yielding patient-specific renewable cells without raising ethical concerns related to the use of embryonic stem cells. In two decades, iPSC therapies have advanced from basic research to clinical trials and official approvals. Early research focused on autologous transplantation, exemplified by the 2014 retinal pigment epithelium (RPE) graft. Yet, personalized production obstacles prompted allogeneic schemes relying on HLA cell banks and immunomodified donor cells. Meanwhile, innovations such as chemical reprogramming have revitalized autologous strategies. Today, autologous and allogeneic iPSC therapies complement each other for distinct clinical demands. This review traces key field milestones and analyzes prospects and hurdles for next-generation iPSC therapies.
The article traces the trend of directed differentiation technologies evolving from two-dimensional culture to three-dimensional organoids and details their practical applications in diseases such as stroke, Alzheimer's disease, and spinal cord injury—particularly in spinal cord injury models, where transplanted cells have achieved long-distance axonal regeneration and circuit reconstruction.
Dai-Yi Yang· International Journal of Bio...· 0 citations
An immunological perspective is provided on how the breadth of rejection mechanisms that have been uncovered through decades of research and the relative simplicity of designing PSC immune evasion strategies to circumvent these mechanisms apply to the treatment of type 1 diabetes are discussed.
Key applications of iPSC technology in hemato-oncology are summarized, its major advantages and current limitations are discussed, and emerging directions are highlighted, including scalable iPSC-derived blood cell therapies for inherited and acquired bone marrow failure syndromes and leukemia.
Ivan Tesakov, M. Nasri, M. Klimiankou et al.· Frontiers in Immunology· 0 citations
This review summarizes the trajectory of iPSC reprogramming technologies and identifies the core “translational triltrilas”, namely, the inherent tradeoffs between security, homogeneity, and scalability, and proposes a comprehensive strategy to overcome these bottlenecks.
Mengmeng Chen, Ning Zuo, Qi Wang et al.· Frontiers in Cell and Develo...· 0 citations
This Review evaluates the technological and translational trajectories that have defined the iPSC era and analyzes the operational barriers to therapeutic development, envisioning a paradigm shift in which iPSC-derived interventions transition from bespoke experimental models toward standardized, engineered biological medicines.
Jaecheol Lee, Todd J. Herron, Lorenz Studer et al.· Nature Medicine· 0 citations
Over the past three decades, advances in human pluripotent stem cell (hPSC) technologies, including induced pluripotent stem cells, gene editing, and 2D/3D models, have transformed biomedical research. These powerful tools have revolutionized disease modeling, drug discovery, and the development of advanced therapy medicinal products (ATMPs), while driving the establishment of stem cell core facilities. By providing specialized expertise, standardized workflows, and access to advanced technologies, these facilities support both fundamental and translational research, promote rigor and reproducibility, and foster collaboration. This manuscript highlights their role as hubs of excellence and discusses current challenges and future opportunities for the global stem cell community.
B. Corneo, G. Fagà, Inês Figueira et al.· Stem Cell Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
